Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Specific escalation schedules varied by trial protocol, and the full range of doses studied is described in the published Phase 2 trial data
At 72 weeks, people taking tirzepatide lost an average of 20.2% of their body weight, compared with 13.7% for those taking semaglutide
In the SURMOUNT-1 trial, tirzepatide produced average weight loss of: 5 mg dose: 15.0% body weight reduction 10 mg dose: 19.5% body weight reduction 15 mg dose: 20.9% body weight reduction These results came from 72 weeks of carefully titrated, medically supervised treatment
The American College of Physicians guidelines note that continued treatment is necessary to maintain weight loss, as discontinuation often leads to weight regain
Less convenient for self-administration but provides site rotation options
US$ 20.82
US$ 25.40
US$ 26.25
